RecruitingNot ApplicableNCT07295691

Autologous Serum Eye Drops in Dry Eye Syndrome

Autologous Serum Eye Drops in Dry Eye Syndrome: Clinical Efficacy and Safety Evaluation


Sponsor

The General Authority for Teaching Hospitals and Institutes

Enrollment

70 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to evaluate the clinical efficacy and safety of autologous serum eye drops (ASEDs) in patients with moderate-to-severe dry eye syndrome who are refractory to conventional artificial tear therapy.


Eligibility

Max Age: 18 Years

Inclusion Criteria3

  • Children aged less than 18 years.
  • Both sexes.
  • Diagnosed with moderate to severe dry eye syndrome (DES) refractory to artificial tears.

Exclusion Criteria4

  • Active ocular infection.
  • Recent ocular surgery.
  • Systemic immunosuppressive therapy.
  • History of allergy to blood-derived products.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAutologous Serum Eye Drop

Participants will receive eye drops prepared from their blood serum following a standardized protocol. Specifically, 40 mL of venous blood was collected from each participant at the start of the study and centrifuged at 3000 rpm for 15 min.


Locations(1)

The General Authority for Teaching Hospitals and Institutes

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07295691